Requirements for Successful Completion: Complete the learning activity in its entirety and complete the online CNE evaluation.
Authors Conflict of Interest Disclosure: The author(s) reported no actual or potential conflict of interest in relation to this continuing nursing education activity.
Nephrology Nursing Journal Editorial Board Statements of Disclosure: Deborah H. Brooks, MSN, APN-BC, CNNNP, disclosed that she is on the Consultant Presenter Bureau and the Advisory Board for Affymax, Inc.
Paula Dutka, MSN, RN, CNN, disclosed that she has received grant/research support from Keryx, Amgen, Rockwell, Fibrogen, Dynovox, and Otsuka; and she is on the Consultant and Presenter Bureau and the Nephrology Nurse Advisory Board for Affymax/Takeda.
Patricia B. McCarley, MSN, RN, ACNPc, CNN, disclosed that she is on the Consultant Presenter Bureau for Amgen, Genzyme, and OrthoBiotech. She is also on the Advisory Board for Amgen, Genzyme, and Roche and is the recipient of unrestricted educational grants from OrthoBiotech and Roche.
All other members of the Editorial Board had no actual or potential conflict of interest in relation to this continuing nursing education activity.
This article was reviewed and formatted for contact hour credit by Beth Ulrich, EdD, RN, FACHE, FAAN, Nephrology Nursing Journal Editor, and Hazel A. Dennison, DNP, RN, APNc, CPHQ, CNE, ANNA Education Director.
Commercial Support and Sponsorship: No commercial support or sponsorship declared.
Accreditation Statement: American Nephrology Nurses' Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
ANNA is a provider approved by the California Board of Registered Nursing, provider number CEP 00910.
Goal To provide an overview of calciphylaxis and its treatment options.
List the factors that predispose patients with end stage renal disease to calciphylaxis.
Discuss treatment options for patients with calciphylaxis.